| Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ... Jama 324 (8), 772-781, 2020 | 1043 | 2020 |
| Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ... Nature medicine 26 (3), 379-386, 2020 | 1019 | 2020 |
| Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration EH Thijssen, R La Joie, A Wolf, A Strom, P Wang, L Iaccarino, ... Nature medicine 26 (3), 387-397, 2020 | 634 | 2020 |
| Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography MM Mielke, CE Hagen, J Xu, X Chai, P Vemuri, VJ Lowe, DC Airey, ... Alzheimer's & Dementia 14 (8), 989-997, 2018 | 560 | 2018 |
| Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease S Janelidze, E Stomrud, R Smith, S Palmqvist, N Mattsson, DC Airey, ... Nature communications 11 (1), 1683, 2020 | 387 | 2020 |
| Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures S Palmqvist, P Tideman, N Cullen, H Zetterberg, K Blennow, ... Nature medicine 27 (6), 1034-1042, 2021 | 378 | 2021 |
| Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study EH Thijssen, R La Joie, A Strom, C Fonseca, L Iaccarino, A Wolf, S Spina, ... The Lancet Neurology 20 (9), 739-752, 2021 | 358 | 2021 |
| Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease M Milà-Alomà, NJ Ashton, M Shekari, G Salvadó, P Ortiz-Romero, ... Nature Medicine 28 (9), 1797-1801, 2022 | 318 | 2022 |
| Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease S Palmqvist, PS Insel, E Stomrud, S Janelidze, H Zetterberg, B Brix, ... EMBO molecular medicine 11 (12), e11170, 2019 | 306 | 2019 |
| Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease N Mattsson-Carlgren, E Andersson, S Janelidze, R Ossenkoppele, P Insel, ... Science advances 6 (16), eaaz2387, 2020 | 285 | 2020 |
| Performance of plasma phosphorylated tau 181 and 217 in the community MM Mielke, JL Dage, RD Frank, A Algeciras-Schimnich, DS Knopman, ... Nature medicine 28 (7), 1398-1405, 2022 | 273 | 2022 |
| Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease S Janelidze, D Berron, R Smith, O Strandberg, NK Proctor, JL Dage, ... JAMA neurology 78 (2), 149-156, 2021 | 270 | 2021 |
| Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study AM Brickman, JJ Manly, LS Honig, D Sanchez, D Reyes‐Dumeyer, ... Alzheimer's & Dementia 17 (8), 1353-1364, 2021 | 267 | 2021 |
| Constitutive secretion of tau protein by an unconventional mechanism X Chai, JL Dage, M Citron Neurobiology of disease 48 (3), 356-366, 2012 | 267 | 2012 |
| Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease N Mattsson-Carlgren, S Janelidze, S Palmqvist, N Cullen, ... Brain 143 (11), 3234-3241, 2020 | 231 | 2020 |
| Blood‐based biomarkers for Alzheimer's disease A Leuzy, N Mattsson‐Carlgren, S Palmqvist, S Janelidze, JL Dage, ... EMBO molecular medicine 14 (1), e14408, 2022 | 227 | 2022 |
| Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging MM Mielke, CE Hagen, AMV Wennberg, DC Airey, R Savica, ... JAMA neurology 74 (9), 1073-1080, 2017 | 212 | 2017 |
| Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations NC Cullen, A Leuzy, S Janelidze, S Palmqvist, AL Svenningsson, ... Nature communications 12 (1), 3555, 2021 | 196 | 2021 |
| Blood biomarkers for Alzheimer’s disease in clinical practice and trials O Hansson, K Blennow, H Zetterberg, J Dage Nature aging 3 (5), 506-519, 2023 | 190 | 2023 |
| Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes MM Mielke, RD Frank, JL Dage, A Jeromin, NJ Ashton, K Blennow, ... JAMA neurology 78 (9), 1108-1117, 2021 | 169 | 2021 |
